Everence Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Everence Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,760	Closed	-$276K	–	941
2024 Q3	$276K	Buy	+2,760	New	+$278K	0.02%	625
2024 Q2	–	Sell	-2,760	Closed	-$202	–	750
2024 Q1	$202	Buy	+2,760	New	+$203K	0.01%	716
2023 Q2	–	Sell	-2,760	Closed	-$203	–	736
2023 Q1	$203	Buy	+2,760	New	+$196K	0.02%	678
2022 Q4	–	Sell	-4,424	Closed	-$238K	–	782
2022 Q3	$238K	Hold	4,424	–	–	0.02%	598
2022 Q2	$246K	Hold	4,424	–	–	0.02%	579
2022 Q1	$310K	Hold	4,424	–	–	0.02%	549
2021 Q4	$426K	Buy	+4,424	New	+$409K	0.03%	474
2018 Q4	–	Sell	-2,741	Closed	-$469K	–	436
2018 Q3	$469K	Hold	2,741	–	–	0.09%	235
2018 Q2	$354K	Buy	2,741 +705	+35%	+$78.7K	0.07%	279
2018 Q1	$210K	Buy	+2,036	New	+$201K	0.05%	385

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everence Capital Management's LGND Position: Q4 2024 in Review

Everence Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 2,760 shares — an estimated $276K sold.

Everence Capital Management first reported a position in LGND in Q1 2018 and held it in 10 quarters. The position peaked at $469K in Q3 2018. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

Everence Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Everence Capital Management sold 2,760 Ligand Pharmaceuticals shares in Q4 2024, an estimated $276K.
Everence Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Everence Capital Management's Ligand Pharmaceuticals position peaked at $469K in Q3 2018.
258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.